Prostate cancer cells with BRCA2 deficiency may tolerate the genomic and chromosomal instability caused by BRCA2 deficiency by silencing SAC activation in the process of cancer occurrence and progression. This evidence concerns the gene BRCA2 and prostate carcinoma.